{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:04:16Z","timestamp":1785899056054,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10637-025-01528-5","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T09:11:04Z","timestamp":1745658664000},"page":"405-424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Glasdegib combined with chemotherapy in the treatment of patients with acute myeloid leukemia: a comprehensive meta-analysis"],"prefix":"10.1007","volume":"43","author":[{"given":"Abdelaziz A.","family":"Awad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Yasser","family":"Shaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Mahmoud","family":"Marey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Aldemerdash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed W.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Elhady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israa","family":"Sharabati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed R. A.","family":"Abou-Shanab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Bahnasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussien Ahmed H.","family":"Abdelgawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"issue":"12","key":"1528_CR1","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/cncr.33458","volume":"127","author":"K Sasaki","year":"2021","unstructured":"Sasaki K et al (2021) De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980 to 2017. Cancer 127(12):2049\u20132061. https:\/\/doi.org\/10.1002\/cncr.33458","journal-title":"Cancer"},{"issue":"3","key":"1528_CR2","first-page":"38","volume":"103","author":"A Pelcovits","year":"2020","unstructured":"Pelcovits A, Niroula R (2020) Acute myeloid leukemia: a review. R I Med J 103(3):38\u201340","journal-title":"R I Med J"},{"issue":"2","key":"1528_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000536152","volume":"147","author":"F Wachter","year":"2024","unstructured":"Wachter F, Pikman Y (2024) Pathophysiology of acute myeloid leukemia. Acta Haematol 147(2):229\u2013246. https:\/\/doi.org\/10.1159\/000536152","journal-title":"Acta Haematol"},{"issue":"1","key":"1528_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.hoc.2009.11.008","volume":"24","author":"JE Rubnitz","year":"2010","unstructured":"Rubnitz JE, Gibson B, Smith FO (2010) Acute myeloid leukemia. Hematol Oncol Clin North Am 24(1):35\u201363. https:\/\/doi.org\/10.1016\/j.hoc.2009.11.008","journal-title":"Hematol Oncol Clin North Am"},{"issue":"16 Suppl","key":"1528_CR5","first-page":"S347","volume":"24","author":"M Wiese","year":"2018","unstructured":"Wiese M, Daver N (2018) Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemia. Am J Manag Care 24(16 Suppl):S347\u2013S355","journal-title":"Am J Manag Care"},{"issue":"21","key":"1528_CR6","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30(21):2670\u20132677. https:\/\/doi.org\/10.1200\/JCO.2011.38.9429","journal-title":"J Clin Oncol"},{"issue":"6","key":"1528_CR7","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/cncr.22496","volume":"109","author":"AK Burnett","year":"2007","unstructured":"Burnett AK et al (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109(6):1114\u20131124. https:\/\/doi.org\/10.1002\/cncr.22496","journal-title":"Cancer"},{"issue":"7","key":"1528_CR8","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2011.59","volume":"25","author":"AK Burnett","year":"2011","unstructured":"Burnett AK et al (2011) The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia 25(7):1122\u20131127. https:\/\/doi.org\/10.1038\/leu.2011.59","journal-title":"Leukemia"},{"issue":"5","key":"1528_CR9","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/14656566.2020.1713094","volume":"21","author":"X Thomas","year":"2020","unstructured":"Thomas X, Heiblig M (2020) An evaluation of glasdegib for the treatment of acute myelogenous leukemia. Expert Opin Pharmacother 21(5):523\u2013530. https:\/\/doi.org\/10.1080\/14656566.2020.1713094","journal-title":"Expert Opin Pharmacother"},{"key":"1528_CR10","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.2147\/CMAR.S195723","volume":"14","author":"SG Iyer","year":"2022","unstructured":"Iyer SG, Stanchina M, Bradley TJ, Watts J (2022) Profile of glasdegib for the treatment of newly diagnosed acute myeloid leukemia (AML): evidence to date. CMAR 14:2267\u20132272. https:\/\/doi.org\/10.2147\/CMAR.S195723","journal-title":"CMAR"},{"issue":"2","key":"1528_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40265-018-1047-7","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy SM (2019) Glasdegib: first global approval. Drugs 79(2):207\u2013213. https:\/\/doi.org\/10.1007\/s40265-018-1047-7","journal-title":"Drugs"},{"issue":"14","key":"1528_CR12","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1080\/14656566.2023.2232301","volume":"24","author":"A Bruzzese","year":"2023","unstructured":"Bruzzese A et al (2023) Glasdegib for the treatment of acute myeloid leukemia. Expert Opin Pharmacother 24(14):1537\u20131543. https:\/\/doi.org\/10.1080\/14656566.2023.2232301","journal-title":"Expert Opin Pharmacother"},{"key":"1528_CR13","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.\u00a0Int J Surg 8(5): 336-341","DOI":"10.1016\/j.ijsu.2010.02.007"},{"key":"1528_CR14","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"J Chandler","year":"2019","unstructured":"Chandler J, Cumpston M, Li T, Page MJ, Welch V (2019) Cochrane handbook for systematic reviews of interventions. Wiley, Hoboken"},{"issue":"1","key":"1528_CR15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"issue":"1","key":"1528_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ (2021) IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol 21(1):111. https:\/\/doi.org\/10.1186\/s12874-021-01308-8","journal-title":"BMC Med Res Methodol"},{"key":"1528_CR17","doi-asserted-by":"publisher","unstructured":"Sterne JA et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj 366. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"1528_CR18","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from:\u00a0http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"1528_CR19","doi-asserted-by":"publisher","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2009) Effect sizes based on means . In: Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (eds) Introduction to meta-analysis.\u00a0https:\/\/doi.org\/10.1002\/9780470743386.ch4","DOI":"10.1002\/9780470743386.ch4"},{"key":"1528_CR20","unstructured":"R Core Team R (2013) R: a language and environment for statistical computing. [Online]. Available: https:\/\/www.R-project.org\/. Accessed 20 Dec 2024"},{"key":"1528_CR21","doi-asserted-by":"crossref","unstructured":"Harrer M, Cuijpers P, Furukawa TA, Ebert DD (2021) Doing meta-analysis with r: a hands-on guide. Boca Raton, FL and London: Chapman & Hall\/CRC Press","DOI":"10.1201\/9781003107347"},{"issue":"43","key":"1528_CR22","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H et al (2019) Welcome to the Tidyverse. J Open Source Softw 4(43):1686. https:\/\/doi.org\/10.21105\/joss.01686","journal-title":"J Open Source Softw"},{"issue":"8","key":"1528_CR23","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s00277-022-04853-4","volume":"101","author":"MA Sekeres","year":"2022","unstructured":"Sekeres MA et al (2022) A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes. Ann Hematol 101(8):1689\u20131701. https:\/\/doi.org\/10.1007\/s00277-022-04853-4","journal-title":"Ann Hematol"},{"issue":"10","key":"1528_CR24","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1038\/s41375-023-02001-z","volume":"37","author":"MA Sekeres","year":"2023","unstructured":"Sekeres MA et al (2023) Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial. Leukemia 37(10):2017\u20132026. https:\/\/doi.org\/10.1038\/s41375-023-02001-z","journal-title":"Leukemia"},{"issue":"2","key":"1528_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","volume":"33","author":"JE Cortes","year":"2019","unstructured":"Cortes JE et al (2019) Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia 33(2):379\u2013389. https:\/\/doi.org\/10.1038\/s41375-018-0312-9","journal-title":"Leukemia"},{"issue":"11","key":"1528_CR26","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/ajh.25238","volume":"93","author":"JE Cortes","year":"2018","unstructured":"Cortes JE et al (2018) Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results. Am J Hematol 93(11):1301\u20131310. https:\/\/doi.org\/10.1002\/ajh.25238","journal-title":"Am J Hematol"},{"issue":"5","key":"1528_CR27","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00277-021-04471-6","volume":"100","author":"A Zucenka","year":"2021","unstructured":"Zucenka A et al (2021) Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients. Ann Hematol 100(5):1195\u20131202. https:\/\/doi.org\/10.1007\/s00277-021-04471-6","journal-title":"Ann Hematol"},{"issue":"4","key":"1528_CR28","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/cas.16054","volume":"115","author":"K Izutsu","year":"2024","unstructured":"Izutsu K et al (2024) Glasdegib with intensive\/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high-risk myelodysplastic syndromes. Cancer Sci 115(4):1250\u20131260. https:\/\/doi.org\/10.1111\/cas.16054","journal-title":"Cancer Sci"},{"issue":"10","key":"1528_CR29","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1158\/1078-0432.CCR-17-2824","volume":"24","author":"MR Savona","year":"2018","unstructured":"Savona MR et al (2018) Phase Ib study of glasdegib, a hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS. Clin Cancer Res 24(10):2294\u20132303. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2824","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1528_CR30","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00277-021-04465-4","volume":"100","author":"M Heuser","year":"2021","unstructured":"Heuser M et al (2021) Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Ann Hematol 100(5):1181\u20131194. https:\/\/doi.org\/10.1007\/s00277-021-04465-4","journal-title":"Ann Hematol"},{"issue":"10","key":"1528_CR31","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.exphem.2013.05.287","volume":"41","author":"AL Boyd","year":"2013","unstructured":"Boyd AL, Salci KR, Shapovalova Z, McIntyre BA, Bhatia M (2013) Nonhematopoietic cells represent a more rational target of in vivo hedgehog signaling affecting normal or acute myeloid leukemia progenitors. Exp Hematol 41(10):858\u2013869. https:\/\/doi.org\/10.1016\/j.exphem.2013.05.287","journal-title":"Exp Hematol"},{"issue":"26","key":"1528_CR32","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1182\/blood-2016-05-718585","volume":"129","author":"P Chaudhry","year":"2017","unstructured":"Chaudhry P, Singh M, Triche TJ, Guzman M, Merchant AA (2017) GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML. Blood 129(26):3465\u20133475. https:\/\/doi.org\/10.1182\/blood-2016-05-718585","journal-title":"Blood"},{"issue":"2","key":"1528_CR33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y (2020) FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci 111(2):312\u2013322. https:\/\/doi.org\/10.1111\/cas.14274","journal-title":"Cancer Sci"},{"issue":"13","key":"1528_CR34","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ et al (2024) Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol 42(13):1499\u20131508. https:\/\/doi.org\/10.1200\/JCO.23.01911","journal-title":"J Clin Oncol"},{"issue":"10","key":"1528_CR35","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1200\/JCO.23.00943","volume":"42","author":"NH Russell","year":"2024","unstructured":"Russell NH et al (2024) Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed AML and overall survival in patients with NPM1 and FLT3 mutations. J Clin Oncol 42(10):1158\u20131168. https:\/\/doi.org\/10.1200\/JCO.23.00943","journal-title":"J Clin Oncol"},{"key":"1528_CR36","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2147\/CEOR.S203482","volume":"11","author":"G Tremblay","year":"2019","unstructured":"Tremblay G et al (2019) Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons. ClinicoEcon Outcomes Res 11:551\u2013565. https:\/\/doi.org\/10.2147\/CEOR.S203482","journal-title":"ClinicoEcon Outcomes Res"},{"issue":"Supplement 1","key":"1528_CR37","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1182\/blood-2018-99-111132","volume":"132","author":"S Lin","year":"2018","unstructured":"Lin S, Shaik MN, Chan G, Cortes JE, Ruiz-Garcia A (2018) Population pharmacokinetic\/pharmacodynamic evaluation of the relationship between glasdegib treatment\/ exposure and overall survival in AML patients. Blood 132(Supplement 1):1450\u20131450. https:\/\/doi.org\/10.1182\/blood-2018-99-111132","journal-title":"Blood"},{"issue":"1","key":"1528_CR38","doi-asserted-by":"publisher","first-page":"2343604","DOI":"10.1080\/16078454.2024.2343604","volume":"29","author":"H He","year":"2024","unstructured":"He H, Wen X, Zheng H (2024) Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis. Hematology 29(1):2343604. https:\/\/doi.org\/10.1080\/16078454.2024.2343604","journal-title":"Hematology"},{"issue":"7","key":"1528_CR39","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"issue":"16","key":"1528_CR40","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.2217\/fon-2018-0842","volume":"15","author":"CM Mamolo","year":"2019","unstructured":"Mamolo CM et al (2019) A real-world, cross-sectional, community survey of symptoms and health-related quality of life of adults with acute myeloid leukemia. Future Oncol 15(16):1895\u20131909. https:\/\/doi.org\/10.2217\/fon-2018-0842","journal-title":"Future Oncol"},{"key":"1528_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/CEOR.S187409","volume":"11","author":"A Forsythe","year":"2019","unstructured":"Forsythe A, Kwon CS, Bell T, Smith TA, Arondekar B (2019) Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review. ClinicoEcon Outcomes Res 11:87\u201398. https:\/\/doi.org\/10.2147\/CEOR.S187409","journal-title":"ClinicoEcon Outcomes Res"},{"issue":"5","key":"1528_CR42","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1080\/10428194.2019.1709838","volume":"61","author":"SA Buckley","year":"2020","unstructured":"Buckley SA, Halpern AB, Othus M, Jimenez-Sahagun D, Walter RB, Lee SJ (2020) Development and validation of the AML-QOL: a quality of life instrument for patients with acute myeloid leukemia. Leuk Lymphoma 61(5):1158\u20131167. https:\/\/doi.org\/10.1080\/10428194.2019.1709838","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1528_CR43","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1080\/13696998.2021.1875743","volume":"24","author":"Y Hu","year":"2021","unstructured":"Hu Y, Charaan M, van Oostrum I, Heeg B, Bell T (2021) The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada. J Med Econ 24(1):150\u2013161. https:\/\/doi.org\/10.1080\/13696998.2021.1875743","journal-title":"J Med Econ"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01528-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01528-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01528-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:40:22Z","timestamp":1746193222000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01528-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1528"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01528-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}